Doctors Prescribe GLP-1 Drugs to Children as Young as 6 Despite No Approval
Updated
Updated · The Independent · Jun 22
Doctors Prescribe GLP-1 Drugs to Children as Young as 6 Despite No Approval
3 articles · Updated · The Independent · Jun 22
Summary
Children as young as 6 are receiving off-label GLP-1 obesity drugs from some doctors seeking to curb lifelong weight problems before complications such as Type 2 diabetes and high blood pressure set in.
U.S. regulators approve obesity use only from age 12, though Novo Nordisk and Eli Lilly are testing these medicines in children 6 and older; GLP-1s are also cleared for Type 2 diabetes from age 10.
Two 9-year-old twins in Atlanta began Wegovy after years of failed diet and exercise efforts, elevated A1C, liver dysfunction and a genetic mutation affecting fullness; their parents pay about $700 every four weeks.
The boys' BMI has fallen 5% and 7%, but many pediatric specialists say evidence is still too thin to support obesity prescribing under 12 and warn about nutrition risks and unknown decades-long effects.
The debate lands as about 21% of Americans ages 2 to 19 have obesity, underscoring pressure for earlier treatment even as long-term pediatric data remain limited.
For children on powerful weight-loss drugs, what happens when the medication eventually stops?
Are we solving childhood obesity or creating lifelong dependency on pharmaceuticals?
Genetic tests can predict a drug's success. Should they decide which children get this treatment?
GLP-1 Medications for Childhood Obesity: Efficacy, Safety, Access, and the Expanding Use in Children as Young as Six
Overview
GLP-1 medications are changing how childhood obesity is treated, with some already approved for teenagers and showing strong benefits like a 16.1% reduction in BMI. These results are considered healthy and meaningful, leading to more discussions and trials for even younger children. Real-world stories, such as a 16-year-old losing 42 pounds and feeling happier and more confident, highlight the positive impact. The success in older kids is driving interest in expanding GLP-1 use, but questions remain about long-term effects and safety, especially as research moves toward treating children as young as six.